Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.

BACKGROUND Retinopathy is a serious complication related to prematurity and a leading cause of childhood blindness. The aggressive posterior form of retinopathy of prematurity (APROP) has a worse anatomical and functional outcome following laser therapy, as compared with the classic form of the disease. The main outcome measures are the APROP regression rate, structural outcomes, and complications associated with intravitreal bevacizumab (IVB) versus laser photocoagulation in APROP.

Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity.

Purpose. This study aims to evaluate the regression of retinopathy of prematurity (ROP) after one intravitreal injection of bevacizumab and the factors that influenced it. Methods.

[Retinopathy of prematurity--screening results].

Objective: Analysis of the results of screening for retinopathy of prematurity (ROP) in a sample of prematurely born babies evaluated in the Institute for Mother and Child Care, between September 2002 - 31st December 2007.

Materials And Method: A data base of premies screened for retinopathy of prematurity in our clinic and also those referred sporadically from different neonatal units from other towns (1783 babies) was set up, and this was used to analyze aspects referring to the ROP incidence, as well as outcomes of laser treatment.

Results: A total of 1783 preterm babies were examined, overall incidence of ROP was 55%.